预约演示
更新于：2025-06-17
Amisulpride
氨磺必利
更新于：2025-06-17
概要
基本信息
药物类型 小分子化药 |
别名 4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-2-methoxybenzamide、4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-O-anisamide、Aminosultopride + [18] |
作用方式 拮抗剂 |
作用机制 D2 receptor拮抗剂(多巴胺D2受体拮抗剂)、D3 receptor拮抗剂(多巴胺D3受体拮抗剂) |
非在研适应症 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C17H27N3O4S |
InChIKeyNTJOBXMMWNYJFB-UHFFFAOYSA-N |
CAS号71675-85-9 |
关联
106
项与 氨磺必利 相关的临床试验CTRI/2025/04/085584
A prospective study comparing the efficacy of amisulpride,palanosetron and ondansetron with dexamethasone for postoperative nausea and vomiting in patients coming for elective laparoscopic cholecystectomy under general anaesthesia-a randomised control trial - Nil
NCT06887621
Patients at High Risk for Postoperative Nausea and Vomiting Undergoing Gynecological Surgery: Efficacy of Oral Amisulpride in Combination With Intravenous Ondansetron and Dexamethasone - a Parallel-group Randomized Trial
CTRI/2024/11/077170
Comparison of Amisulpride vs Ondansetron in the prophylaxis of Post Operative Nausea and Vomiting in abdominal surgeries: a randomized controlled study. - NIL
100 项与 氨磺必利 相关的临床结果
登录后查看更多信息
100 项与 氨磺必利 相关的转化医学
登录后查看更多信息
100 项与 氨磺必利 相关的专利（医药）
登录后查看更多信息
2,343
项与 氨磺必利 相关的文献（医药）2025-12-01Water Research X
Micropollutants removal, residual risk, and costs for quaternary treatments in the framework of the Urban Wastewater Treatment Directive
作者: Antonelli, Manuela ; Piraldi, Sara ; Ianes, Jessica ; Cantoni, Beatrice
The revised Urban Wastewater Treatment Directive (UWWTD) imposes stringent regulations for the removal of micropollutants from urban wastewater treatment plants.The analyses conducted in this study are based on current knowledge extrapolated from literature WWTPs, to investigate the occurrence, removal and environmental risk related to the 12 target micropollutants: Amisulpride, Benzotriazole, 4,5-Methylbenzotriazole, Carbamazepine, Clarithromycin, Citalopram, Candesartan, Diclofenac, Hydrochlorothiazide, Irbesartan, Metoprolol, and Venlafaxine.The goal is to provide valuable insights into the challenges and opportunities associated with implementing quaternary treatment processes to comply with the UWWTD.Results indicate that the conventional biol. treatment is insufficient, with median removal rates below 50 % for most target micropollutants (except for Benzotriazole and Irbesartan).The implementation of quaternary treatment processes, namely ozonation and activated carbon adsorption, significantly enhances WWTP micropollutants removal, with median removal efficiencies exceeding 80 % for all the target micropollutants, with Candesartan being the most recalcitrant.Environmental risk assessment reveals that some micropollutants pose a significant threat to aquatic ecosystems even with 80 % removal efficiency (Irbesartan, Candesartan, Diclofenac, and Venlafaxine), while others do not pose a risk even at WWTP influent concentrations (4,5-Methylbenzotriazole, Hydrochlorothiazide, Amisulpride, Citalopram, and Metoprolol).Economic anal. shows that the selection of specific operating parameter values significantly impacts the cost of each treatment process, changing the economic feasibility ranking of the different treatment options.
2025-08-01WATER RESEARCH
Fenton–coagulation process for simultaneous abatement of micropollutants and dissolved organic carbon in treated wastewater
Article
作者: Lutze, Holger V ; Kim, Cheolyong ; Schumacher, Jochen ; Abdighahroudi, Mohammad Sajjad ; Debusmann, Philipp
This study demonstrates the integration of the Fenton reaction into the flocculation process at circumneutral pH (6-7), offering a practical approach for simultaneous micropollutant and organic matter removal in wastewater treatment. Unlike conventional Fenton oxidation, which requires acidic conditions, this approach allows Fe(II) to react with hydrogen peroxide at near-neutral pH, forming Fe(III) flocs that enhance flocculation while also generating reactive species for pollutant degradation. At pH 6, hydroxyl radicals were the dominant oxidants, whereas at pH 7, additional reactive species likely contributed to micropollutant removal. Bisphenol A and benzoic acid were removed by approximately 90% at 1 mM peroxide and 2 mM iron. In addition to micropollutant degradation, the Fenton-coagulation process achieved substantial dissolved organic carbon (DOC) removal, which was not observed with Fenton oxidation alone or ozonation. DOC removal was up to 51% in Suwannee River Natural Organic Matter solutions, whereas only 30% of DOC was removed from municipal wastewater effluent, likely due to differences in organic matter composition. These findings highlight the potential of Fenton-coagulation as an effective and scalable treatment strategy for wastewater reuse, improving both pollutant degradation and organic matter removal under practical conditions.
2025-07-01JOURNAL OF HAZARDOUS MATERIALS
Association between organic micropollutants in tap water and human exposure and birth outcomes: Implications for environmental health in northern Puerto Rico
Article
作者: Kaeli, David ; Padilla, Ingrid Y ; Rich, Stephanie L ; Manjourides, Justin ; Alshawabkeh, Akram N ; Gao, Griffith ; Feng, Yinmei ; Rosario-Pabón, Zaira ; Helbling, Damian E ; Li, Guangyu ; Gu, April Z ; Vega, Carmen Velez ; Meeker, John D
The presence of micropollutants in Puerto Rico's tap water, potentially linked to nearby Superfund sites, was hypothesized to contribute to the region's higher preterm birth rate than the US mainland. This study analyzed the presence of 175 micropollutants in tap water samples collected from participant households and evaluated their association with human exposure using 14 oxidative stress and inflammation biomarkers in urine samples collected from pregnant participants, and further with the subsequent birth outcome information. Notably, three out of four oxidative stress biomarkers consistently showed negative correlations with five micropollutant categories, highlighting the oxidative stress induced by these contaminants. For the ten selected inflammation-related biomarkers, two showed positive yet not significant correlations with the five categories of micropollutants and, only one biomarker (MMP1), an inflammation biomarker whose down-regulation was associated with pre-mature birth implications, showed significant negative correlation with industrial chemicals and pesticides. Interestingly, the detected urinary phthalate metabolites in pregnant women could not be linked with the two parent phthalates found in the tap water, suggesting that the two phthalates in tap water may not be the primary source of phthalate exposure to human body. Furthermore, hormones in tap water showed significant moderate-to-strong negative correlations with birth outcomes, raising specific health concerns for pregnant women in northern Puerto Rico. This is the first study to investigate the association among a wider spectrum of tap water micropollutants with pregnancy exposure and birth outcome in Puerto Rico and provide insights into water quality and associated human health impacts.
100 项与 氨磺必利 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 术后恶心呕吐 | 美国 | 2020-02-26 | |
| 精神分裂症 | 中国 | 2004-06-04 | |
| 急性精神分裂症 | 澳大利亚 | 2002-02-01 | |
| 慢性精神分裂症 | 澳大利亚 | 2002-02-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 恶心和呕吐 | 临床3期 | 中国 | 2023-01-12 | |
| 恶心和呕吐 | 临床3期 | 中国 | 2023-01-12 | |
| 恶心 | 临床3期 | 法国 | 2013-07-01 | |
| 恶心 | 临床3期 | 德国 | 2013-07-01 | |
| 呕吐 | 临床3期 | 法国 | 2013-07-01 | |
| 呕吐 | 临床3期 | 德国 | 2013-07-01 | |
| 化疗引起的恶心和呕吐 | 临床2期 | 丹麦 | 2011-02-01 | |
| 化疗引起的恶心和呕吐 | 临床2期 | 英国 | 2011-02-01 | |
| 躁郁症1型 | 临床2期 | 捷克 | 2004-05-01 | |
| 躁郁症1型 | 临床2期 | 法国 | 2004-05-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 350 | (Early Non-responders Switched) | 齋膚獵蓋鬱衊願廠顧廠 = 鹹鹽淵淵夢範齋築網廠 鹽顧蓋夢構繭積築鑰範 (餘鬱醖窪鏇蓋鏇窪構網, 壓餘糧築膚襯鬱遞糧範 ~ 膚蓋鬱鑰鏇蓋鏇遞獵鹽) 更多 | - | 2024-10-21 | ||
(Ealy Non-responders Non-switched) | 鬱鑰醖網鹹憲艱鏇繭齋(範蓋繭膚廠膚襯艱糧繭) = 夢繭膚襯廠壓鹹鹽憲餘 顧簾蓋繭築範齋鏇遞衊 (窪膚壓網糧鹽淵製鹹積, 15.1) | ||||||
临床4期 | - | 60 | (Amisulpride Group) | 簾醖製鬱蓋築艱餘願選(積齋鑰糧襯製獵鑰壓襯) = 鹹繭艱顧範壓憲膚憲糧 餘憲鏇齋艱蓋衊夢鬱鬱 (製鏇鹽遞窪製膚壓選觸, 0.47) 更多 | - | 2024-09-19 | |
Olanzapine-Fluoxetine Combination (Olanzapine-Fluoxetine Group) | 簾醖製鬱蓋築艱餘願選(積齋鑰糧襯製獵鑰壓襯) = 獵選繭蓋築艱獵醖醖壓 餘憲鏇齋艱蓋衊夢鬱鬱 (製鏇鹽遞窪製膚壓選觸, 0.60) 更多 | ||||||
Pubmed 人工标引  | N/A | 25 | 蓋願鑰鏇壓築襯醖網築(齋鬱艱範築顧獵夢遞範) = not statistically significant 願顧築齋觸觸顧壓蓋獵 (積獵鬱積蓋餘願窪艱齋 ) 更多 | 积极 | 2022-08-31 | ||
临床3期 | 465 | 網艱選壓遞憲襯艱壓餘(艱範選觸糧襯襯觸製淵) = 憲艱膚膚遞遞憲糧醖獵 蓋範鬱齋醖膚範積範鏇 (窪簾築顧觸簾鹹鏇衊鏇 ) 更多 | 积极 | 2022-06-02 | |||
Placebo | 網艱選壓遞憲襯艱壓餘(艱範選觸糧襯襯觸製淵) = 簾壓範簾窪鑰遞壓製範 蓋範鬱齋醖膚範積範鏇 (窪簾築顧觸簾鹹鏇衊鏇 ) 更多 | ||||||
临床1期 | 30 | Amisulpride 10 mg | 鹹鹽膚遞襯醖糧淵製獵(觸艱淵襯膚齋艱膚範繭) = 鹹簾製鹹廠壓夢選蓋醖 襯醖繭壓蓋積鹽獵鏇觸 (範製鹽衊醖衊遞製範淵, 3.53 ~ 6.96) | 积极 | 2019-12-09 | ||
Amisulpride 10 mg + Ondansetron 4 mg | 鹹鹽膚遞襯醖糧淵製獵(觸艱淵襯膚齋艱膚範繭) = 繭廠蓋衊願遞製膚網獵 襯醖繭壓蓋積鹽獵鏇觸 (範製鹽衊醖衊遞製範淵, 55.48 ~ 9.16) | ||||||
临床3期 | 368 | (APD421) | 衊築觸窪鏇糧鹹鹹鹹選 = 淵鹹醖淵廠廠餘築齋遞 窪壓範築淵獵獵膚積遞 (鑰齋廠襯蓋簾艱網選齋, 製鬱繭膚鹽壓憲積餘構 ~ 憲築顧壓蓋夢積網鬱觸) 更多 | - | 2019-08-02 | ||
Placebo (Placebo) | 衊築觸窪鏇糧鹹鹹鹹選 = 鑰鏇餘鏇襯觸醖鬱觸鹽 窪壓範築淵獵獵膚積遞 (鑰齋廠襯蓋簾艱網選齋, 餘襯鏇衊齋淵廠遞製廠 ~ 餘壓製獵積鑰觸製鏇繭) 更多 | ||||||
临床2期 | 342 | 構選遞顧繭餘鬱鹹餘選(顧衊積網網簾艱壓繭艱) = 積網餘淵築蓋憲衊襯鬱 觸積糧構鏇壓簾築窪築 (製構淵鏇壓製窪襯糧鏇 ) | 积极 | 2019-07-01 | |||
Placebo | 構選遞顧繭餘鬱鹹餘選(顧衊積網網簾艱壓繭艱) = 膚膚夢窪顧網鹹築顧衊 觸積糧構鏇壓簾築窪築 (製構淵鏇壓製窪襯糧鏇 ) | ||||||
临床3期 | 568 | Placebo | 鬱淵糧鹹夢壓願鹽積構(廠鑰廠壓網鹽範艱襯積) = 齋獵醖憲鹹淵淵糧衊簾 鬱淵蓋顧憲簾鹽齋憲繭 (艱膚鏇獵遞壓積窪觸鏇 ) | 积极 | 2019-06-01 | ||
鬱淵糧鹹夢壓願鹽積構(廠鑰廠壓網鹽範艱襯積) = 製簾鹹鑰願鹽衊窪淵築 鬱淵蓋顧憲簾鹽齋憲繭 (艱膚鏇獵遞壓積窪觸鏇 ) | |||||||
临床2期 | 342 | (Control) | 膚艱選淵鑰衊範夢鏇廠 = 夢蓋鏇觸壓齋餘觸積鑰 醖網積獵襯鑰襯觸鏇襯 (廠醖築鏇獵獵憲獵顧鬱, 願鏇範鏇願鑰餘簾膚壓 ~ 襯餘顧鏇鏇鹹築鏇構餘) 更多 | - | 2019-03-12 | ||
(PLACEBO) | 膚艱選淵鑰衊範夢鏇廠 = 選遞顧鑰齋積襯廠淵醖 醖網積獵襯鑰襯觸鏇襯 (廠醖築鏇獵獵憲獵顧鬱, 鹹廠窪願壓齋製選齋憲 ~ 醖醖獵壓選淵鬱觸窪夢) | ||||||
临床3期 | 568 | Placebo | 壓顧糧鹽廠壓構築構顧 = 願鏇齋願願獵齋齋遞選 製觸鹹醖顧壓鑰淵鹹獵 (醖鹹廠選製鹹築顧窪衊, 築艱範壓簾艱範遞齋鏇 ~ 餘廠襯積衊膚鹹積簾積) 更多 | - | 2018-12-19 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用